image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 70.27
-3.16 %
$ 1.52 B
Market Cap
-67.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ANIP stock under the worst case scenario is HIDDEN Compared to the current market price of 70.3 USD, ANI Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ANIP stock under the base case scenario is HIDDEN Compared to the current market price of 70.3 USD, ANI Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ANIP stock under the best case scenario is HIDDEN Compared to the current market price of 70.3 USD, ANI Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANIP

image
$74.0$74.0$72.0$72.0$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.0$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
614 M REVENUE
26.20%
584 K OPERATING INCOME
-98.76%
-18.5 M NET INCOME
-98.63%
64 M OPERATING CASH FLOW
-46.19%
-405 M INVESTING CASH FLOW
-2086.37%
265 M FINANCING CASH FLOW
292.87%
191 M REVENUE
28.48%
-4.38 M OPERATING INCOME
78.66%
-10.3 M NET INCOME
54.04%
15.9 M OPERATING CASH FLOW
27.14%
-10.7 M INVESTING CASH FLOW
97.32%
-4.91 M FINANCING CASH FLOW
-1.69%
Balance Sheet ANI Pharmaceuticals, Inc.
image
Current Assets 528 M
Cash & Short-Term Investments 151 M
Receivables 222 M
Other Current Assets 155 M
Non-Current Assets 756 M
Long-Term Investments 0
PP&E 56.9 M
Other Non-Current Assets 699 M
11.78 %17.27 %12.06 %4.43 %54.46 %Total Assets$1.3b
Current Liabilities 194 M
Accounts Payable 45.7 M
Short-Term Debt 9.17 M
Other Current Liabilities 139 M
Non-Current Liabilities 661 M
Long-Term Debt 615 M
Other Non-Current Liabilities 46.6 M
5.34 %16.24 %71.91 %5.45 %Total Liabilities$855.2m
EFFICIENCY
Earnings Waterfall ANI Pharmaceuticals, Inc.
image
Revenue 614 M
Cost Of Revenue 250 M
Gross Profit 364 M
Operating Expenses 364 M
Operating Income 584 K
Other Expenses 19.1 M
Net Income -18.5 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)614m(250m)364m(364m)584k(19m)(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.27% GROSS MARGIN
59.27%
0.10% OPERATING MARGIN
0.10%
-3.01% NET MARGIN
-3.01%
-4.32% ROE
-4.32%
-1.44% ROA
-1.44%
0.04% ROIC
0.04%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ANI Pharmaceuticals, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.5 M
Depreciation & Amortization 67.7 M
Capital Expenditures -17 M
Stock-Based Compensation 29.3 M
Change in Working Capital 0
Others 7.38 M
Free Cash Flow 47.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ANI Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ANIP of $80.8 , with forecasts ranging from a low of $60 to a high of $94 .
ANIP Lowest Price Target Wall Street Target
60 USD -14.62%
ANIP Average Price Target Wall Street Target
80.8 USD 14.91%
ANIP Highest Price Target Wall Street Target
94 USD 33.77%
Price
Max Price Target
Min Price Target
Average Price Target
9595909085858080757570706565606055555050Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership ANI Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
618 K USD 3
3-6 MONTHS
2.48 M USD 4
6-9 MONTHS
419 K USD 2
9-12 MONTHS
13.8 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ANI Pharmaceuticals: A Short-Term Buying Opportunity ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher. seekingalpha.com - 2 weeks ago
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products. zacks.com - 2 weeks ago
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 weeks ago
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. globenewswire.com - 2 weeks ago
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
3 Reasons Growth Investors Will Love ANI (ANIP) ANI (ANIP) could produce exceptional returns because of its solid growth attributes. zacks.com - 3 weeks ago
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year. zacks.com - 3 weeks ago
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain. zacks.com - 3 weeks ago
5 Stocks With Recent Price Strength Amid Tariff-Led Volatility Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI. zacks.com - 3 weeks ago
4 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue. zacks.com - 4 weeks ago
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 1 month ago
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) ANI (ANIP) could produce exceptional returns because of its solid growth attributes. zacks.com - 1 month ago
8. Profile Summary

ANI Pharmaceuticals, Inc. ANIP

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.52 B
Dividend Yield 0.04%
Description ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Contact 210 Main Street West, Baudette, MN, 56623 https://www.anipharmaceuticals.com
IPO Date May 5, 2000
Employees 897
Officers Mr. Stephen P. Carey Senior Vice President of Finance & Chief Financial Officer Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, Chief Operating Officer of New Jersey Operations & Director Mr. Ori Gutwerg Senior Vice President of Generics Ms. Krista L. Davis Senior Vice President & Chief Human Resources Officer Mr. Chad Gassert Senior Vice President of Corporate Development & Strategy Dr. Mary Pao M.D., Ph.D. Chief Medical Officer Ms. Meredith W. Cook J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Christopher K. Mutz Senior Vice President & Head of Rare Disease Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease Mr. Nikhil Lalwani President, Chief Executive Officer & Director